StockData

Biomerica vs VolitionRx

BMRA and VNRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BMRA and VNRX compare

Biomerica is the larger company, worth 2.2 times as much as VolitionRx ($5.7M against $2.6M).

VolitionRx grew revenue faster over the last twelve months (86.3% versus −11.2% for Biomerica).

Biomerica keeps more of each dollar of sales as profit, with a net margin of −115% compared with −1043% at VolitionRx.

Biomerica scores higher on the StockData Score (8 against 4 for VolitionRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBMRAVNRX
Size and price
Market cap$5.7M$2.6M
Share price$1.24$0.189
Change, 1 year−48.8%−97.2%
Change, 5 years−96.9%−99.7%
Beta (5Y)0.932.26
Employees1775
StockData Score
Total score8 (better)4
Valuation score3 (better)1
Growth score02 (better)
Performance score01 (better)
Health score5 (better)0
Dividend score00
Valuation
P/S1.3×1.0× (better)
P/B1.6×–
FCF yield–−760%
Fair value$2.44–
Margin of safety49.4%–
Growth
Revenue growth (TTM)−11.2%86.3% (better)
Revenue growth, 5Y average−9.2%164% (better)
Profitability
Gross margin0.90%–
Operating margin−125% (better)−790%
Net margin−115% (better)−1043%
FCF margin–−797%
Return on equity−114%–
Return on invested capital−284%–
Financial health
Debt / equity0.00–
Current ratio1.91 (better)0.30
Altman Z-score−10.62 (better)−53.84
Piotroski F-score4 (better)2
Dividends and buybacks
Buyback yield−55.7% (better)−751%
Shareholder yield−55.7% (better)−751%
Ownership
Held by institutions2.7%14.1%
Held by insiders27.4%–
Insider net buying, 12 months$158K (better)$0
Short interest, % of float0.37%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.